Literature DB >> 15657184

Uptake and presentation of hepatitis C virus-like particles by human dendritic cells.

Heidi Barth1, Axel Ulsenheimer, Gerd R Pape, Helmut M Diepolder, Marco Hoffmann, Christoph Neumann-Haefelin, Robert Thimme, Philipp Henneke, Reinhild Klein, Glaucia Paranhos-Baccalà, Erik Depla, T Jake Liang, Hubert E Blum, Thomas F Baumert.   

Abstract

Hepatitis C virus (HCV) is a major cause of chronic hepatitis worldwide. Interaction of dendritic cells (DCs) with viral particles may play an important role in the immunopathogenesis of HCV infection. Since the synthesis or purification of infectious virions is limited, we used HCV-like particles (HCV-LPs) to study the interaction of HCV with human DCs. Immature DCs exhibited an envelope-specific and saturable binding of HCV-LPs, indicating receptor-mediated DC-HCV-LP interaction. Confocal microscopy revealed that HCV-LPs were rapidly taken up by DCs in a temperature-dependent manner. Competition experiments demonstrated that C-type lectins such as mannose receptor or DC-SIGN (DC-specific intercellular adhesion molecule 3-grabbing nonintegrin) were not sufficient for mediating HCV-LP binding. HCV-LP uptake was followed by DC activation. DCs pulsed with HCV-LPs stimulated HCV core-specific CD4(+) T cells, indicating that uptake of HCV-LPs by DCs leads to antigen processing and presentation on major histocompatibility complex (MHC) class II molecules. Finally, HCV-LP-derived antigens were efficiently cross-presented to HCV core-specific CD8(+) T cells. These findings demonstrate that HCV-LPs represent a novel model system to study HCV-DC interaction allowing definition of the molecular mechanisms of HCV uptake, DC activation, and antigen presentation to T cells. Furthermore, HCV-LP-mediated DC activation and efficient antigen presentation may explain the marked immunogenicity of HCV-LPs in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15657184     DOI: 10.1182/blood-2004-05-1952

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

Review 1.  New therapeutic opportunities for hepatitis C based on small RNA.

Authors:  Qiu-Wei Pan; Scot D Henry; Bob J Scholte; Hugo W Tilanus; Harry L A Janssen; Luc J W van der Laan
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

2.  Extra-hepatic infection of hepatitis C virus in the colon tissue and its relationship with hepatitis C virus pathogenesis.

Authors:  Helal F Hetta; Mohamed A Mekky; Nasr K Khalil; Wegdan A Mohamed; Mohamed A El-Feky; Shabaan H Ahmed; Enas A Daef; Ahmed Medhat; Mahmoud I Nassar; Kenneth E Sherman; Mohamed Tarek M Shata
Journal:  J Med Microbiol       Date:  2016-05-10       Impact factor: 2.472

3.  Toll-like receptor 2 senses hepatitis C virus core protein but not infectious viral particles.

Authors:  Marco Hoffmann; Mirjam B Zeisel; Nikolaus Jilg; Glaucia Paranhos-Baccalà; Françoise Stoll-Keller; Takaji Wakita; Peter Hafkemeyer; Hubert E Blum; Heidi Barth; Philipp Henneke; Thomas F Baumert
Journal:  J Innate Immun       Date:  2009-06-23       Impact factor: 7.349

4.  Retrovirus-Based Virus-Like Particle Immunogenicity and Its Modulation by Toll-Like Receptor Activation.

Authors:  Fabien Pitoiset; Thomas Vazquez; Beatrice Levacher; Djamel Nehar-Belaid; Nicolas Dérian; James Vigneron; David Klatzmann; Bertrand Bellier
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

Review 5.  Neutralizing antibodies in hepatitis C virus infection.

Authors:  Mirjam-B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Francoise Stoll-Keller; Michel Doffoel; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

6.  Hepatitis C virus modulates human monocyte-derived dendritic cells.

Authors:  E A Eksioglu; J R Bess; H Zhu; Y Xu; H-J Dong; J Elyar; D R Nelson; C Liu
Journal:  J Viral Hepat       Date:  2010-11       Impact factor: 3.728

7.  Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma.

Authors:  Azza E I El Bassiouny; Nora E I El-Bassiouni; Mona M F Nosseir; Mona M K Zoheiry; Eman G El-Ahwany; Faten Salah; Zeinab S O Omran; Raafat A Ibrahim
Journal:  Medscape J Med       Date:  2008-06-03

8.  Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees.

Authors:  Gamal A Elmowalid; Ming Qiao; Sook-Hyang Jeong; Brian B Borg; Thomas F Baumert; Ronda K Sapp; Zongyi Hu; Krishna Murthy; T Jake Liang
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-07       Impact factor: 11.205

9.  Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells.

Authors:  Heidi Barth; Eva K Schnober; Christoph Neumann-Haefelin; Christine Thumann; Mirjam B Zeisel; Helmut M Diepolder; Zongyi Hu; T Jake Liang; Hubert E Blum; Robert Thimme; Mélanie Lambotin; Thomas F Baumert
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

10.  Analysis of a conserved RGE/RGD motif in HCV E2 in mediating entry.

Authors:  Katharina B Rothwangl; Lijun Rong
Journal:  Virol J       Date:  2009-01-26       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.